Sponsor Hep B foundation
ENYO Pharma takes part to the research against Hepatitis B with the development of its FXR agonist EYP001 and support the research is this field by becoming one of the sponsor of the Hep B Foundation which is “a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide”
Moving to Laënnec
ENYO Pharma will move-in to the new Biosera BioParc Building in Laënnec. It will be a great opportunity as we will be neighbours with Edelris, Erytech Pharma and AB Science. Some CEO, Jean-Yves ORTHOLAND (Edelris), Gil BEYEN (Erytech Pharma) and Jacky VONDERSCHER (ENYO Pharma) recently visited the building under construction.
China Healthcare Investment Conference
26-28 March, 2019
Shanghai
ENYO Pharma has attended the China Healthcare Investment Conference from the 26th to the 28th of March, 2019. It was a great opportunity to initiate several financing and partneurship discussions.
8th Congress of the International Boiron Society
8th of may, 2019
Heidelberg, Germany
Professor Rachel Nechuchstai of the Hebrew University in Jerusalem presented at the 8th Congress of the International Boiron Society in May a lecture entitled “The liability of the NEET proteins’ iron sulphur cluster: biomedical implications”. Professor Nechuchstai presented data generated in part through the close collaboration with ENYO Pharma on this topic.
EASL (European Association for the Study of the Liver)
10-14 April, 2019
Vienna, Austria
ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.
Latest Press Release 